# Hospital Clínico Universitario de Valencia

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/hospital-clinico-universitario-de-valencia/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 93 |
| Citations | 802,007 |
| City | Valencia |
| Country | ES |
| Description | Hospital Clínico Universitario de Valencia is a research organisation in Valencia, ES. OpenAlex records 14,023 works and 802,007 citations for it. 4,053 researchers list it as their most recent affiliation. |
| Homepage | http://clinicomalvarrosa.san.gva.es/ |
| OpenAlex ID | https://openalex.org/I4210094406 |
| Researchers | 4,053 |
| ROR ID | https://ror.org/00hpnj894 |
| Type | healthcare |
| Works | 14,023 |

## University papers

- [Treating rheumatoid arthritis to target: recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-recommendations-of-an-international-task/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-2014-update-of-the-recommendations-of-an/)
- [American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials](https://scholariq.org/papers/american-college-of-rheumatology-european-league-against-rheumatism-provisional/)
- [Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study](https://scholariq.org/papers/comparison-of-tocilizumab-monotherapy-versus-methotrexate-monotherapy-in/)
- [The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement](https://scholariq.org/papers/the-risk-of-tuberculosis-related-to-tumour-necrosis-factor-antagonist-therapies/)
- [A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone](https://scholariq.org/papers/a-phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550/)

## University top topics

Showing 8 of 25.

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Respiratory Support and Mechanisms](https://scholariq.org/topics/respiratory-support-and-mechanisms/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.